These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21994416)

  • 1. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
    Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
    Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
    Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
    BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
    Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
    Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
    Langevin SM; Christensen BC
    Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
    De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
    Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
    Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.
    Ryan BM; Robles AI; Harris CC
    Clin Cancer Res; 2012 Jun; 18(12):3487-8; author reply 3489. PubMed ID: 22669132
    [No Abstract]   [Full Text] [Related]  

  • 10. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
    Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
    Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
    Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
    Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
    Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
    Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.
    Pan XM; Sun RF; Li ZH; Guo XM; Zhang Z; Qin HJ; Xu GH; Gao LB
    Tumour Biol; 2014 Jan; 35(1):831-5. PubMed ID: 23975373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
    Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
    Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
    Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
    PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival.
    Wang D; Liu Q; Ren Y; Zhang Y; Wang X; Liu B
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33825830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
    Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
    Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.
    Kang M; Shen XJ; Kim S; Araujo-Perez F; Galanko JA; Martin CF; Sandler RS; Keku TO
    Cancer Biomark; 2013; 13(5):359-66. PubMed ID: 24440976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
    Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
    Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.